Abstract

BackgroundAmong the most important causes of illness and death in both pregnant women and their newborn infants are respiratory infections including influenza. Pregnant women in North America have a 4 to 5 fold excess rate of hospitalization compared to non-pregnant women. Rates of infant hospitalization associated with influenza are much higher than in their mothers. Fully half of children hospitalized for influenza in the US are in the age group 0–5 months, a group where no vaccine is licensed. Data on influenza are much fewer in low income countries where the risks of serious morbidity and mortality are much higher. A recent trial in Bangladesh suggested that influenza immunization in pregnant women could have important protective effects against influenza in both mothers and their infants. These trials were designed to provide additional evidence about the effect of influenza vaccination in pregnancy in settings where influenza may circulate for up to ten months/year.Methods/DesignWe conducted a consecutive pair of community-based, placebo-controlled, randomized trials of influenza vaccination of pregnant women in a rural district in southern Nepal. Two trials were conducted to insure, as much as possible, the match of circulating strains with those included in the vaccine. Eligible women included all who were or became pregnant over a one year period. Each trial included a one year cohort of pregnant women who were individually randomized to the influenza vaccine available at the time of their enrollment or placebo. Exclusions included a history of allergy to vaccine components, prior influenza vaccine receipt, and for the second trial, participation in the first trial. Morbidity was assessed on a weekly basis for women throughout pregnancy and through 180 days post-partum. Infants were followed weekly through 180 days. Primary outcomes included: 1) incidence of influenza like illness in women, 2) incidence of laboratory confirmed influenza illness in infants, and 3) birthweight among newborn infants.DiscussionWe have presented the design and methods of two randomized trials of influenza immunization of pregnant women.Trial registrationClinicaltrials.gov: (NCT01034254).

Highlights

  • Among the most important causes of illness and death in both pregnant women and their newborn infants are respiratory infections including influenza

  • Individual envelopes were prepared with a sequential serial number on the outside of a sealed envelope

  • Low Birthweight: Data on the expected incidence of low birthweight came from previous studies we have conducted in this area [30]

Read more

Summary

Discussion

We have provided a description of the design and methods used in a consecutive pair of community-based, placebo-controlled, randomized trials of influenza vaccine in pregnant women on respiratory outcomes in the mothers and their infants and in the outcomes of pregnancy conducted in rural Nepal. The most recognized model for this approach is immunization of pregnant women with tetanus toxoid for prevention of neonatal tetanus. This has proven to be highly effective and is a routine practice in almost every country [16]. Authors’ contributions JT, MS, J Katz, JE, and J Kuypers contributed to the design of the study and helped to draft the manuscript. SK, SL, LS, JT and J Katz supervised the conduct of the study in the field. Author details 1Department of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.

Background
Methods
Causes of Febrile Illness
If indicated
Low Birthweight
Influenza-Like-Illness in Women in Pregnancy and through 6 Months Postpartum
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call